Medical Devices New Zealand

New Zealand HPV Testing Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

New Zealand HPV Testing Market Industry Trends and Forecast to 2034: Segmented by (Test, Sample, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

New Zealand · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $13.2 Mn Placeholder estimate
Estimate 2025 $14.7 Mn 0.9% of the global market
Projected 2034 $39.9 Mn 170.7% Adds $25.1 Mn over 9 forecast years
CAGR 2025–2034 11.7% Faster than 67% of 147 Medical Devices markets here
Key players 5
  • New Zealand is 0.9% of the global market.
  • In APAC, the largest is China at $130.7 Mn.
  • Fastest growing: India at 14.8% a year.
  • New Zealand ranks 5th of 10 by size in APAC.

Market size projection

New Zealand

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$25.1 Mn total, 2026–2034

Year-by-year market size, 2024–2034
HPV Testing Market market size by year, New Zealand
YearMarket sizeChange that yearSince 2025
2024 (estimate) $13.2 Mn — —
2025 (base) $14.7 Mn +$1.5 Mn —
2026 (forecast) $16.4 Mn +$1.7 Mn +11.7%
2027 (forecast) $18.4 Mn +$1.9 Mn +24.8%
2028 (forecast) $20.5 Mn +$2.1 Mn +39.4%
2029 (forecast) $22.9 Mn +$2.4 Mn +55.7%
2030 (forecast) $25.6 Mn +$2.7 Mn +73.9%
2031 (forecast) $28.6 Mn +$3.0 Mn +94.2%
2032 (forecast) $31.9 Mn +$3.3 Mn +117%
2033 (forecast) $35.7 Mn +$3.7 Mn +142.3%
2034 (forecast) $39.9 Mn +$4.2 Mn +170.7%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

New Zealand HPV Testing Market Analysis at a glance
Market size, 2025$14.7 Mn placeholder estimate
Forecast, 2034$39.9 Mn placeholder estimate
Growth (CAGR), 2025–203411.7% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsTest, sample and end user (see all)
Key playersRoche Diagnostics, Hologic, Inc., Qiagen N.V., BD (Becton, Dickinson), Abbott Laboratories (see all)
Regulator in New ZealandMedsafe (WAND)Source: Medsafe. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The New Zealand HPV Testing Market Analysis Executive Summary

HPV testing detects human papillomavirus types that can cause cervical cancer, used for cervical screening, including self-collected samples.

Key segments of the HPV Testing market include test (HPV DNA Tests, HPV mRNA Tests and Genotyping Tests) and sample (Clinician-Collected and Self-Collected).

Bar chart: New Zealand HPV Testing market size, 2024–2034, placeholder estimates. $13.2 Mn in 2024, $14.7 Mn in 2025 and $39.9 Mn in 2034, 11.7% CAGR.
New Zealand HPV Testing market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

New Zealand HPV Testing Market Dynamics

Market Growth Drivers

Greater awareness of women's health needs, more funding for female-focused research, later pregnancies and an ageing female population are driving the HPV Testing market. New products designed around women's biology and digital care are improving access.

Opportunity

Femtech, personalised care and new treatments for under-served conditions open strong growth for the HPV Testing market, especially as employers and payers add women's health benefits.

Market Restraints

Under-diagnosis, stigma around some conditions, limited insurance coverage and a long history of under-research in women's health hold back the HPV Testing market.

Competitive Landscape for HPV Testing Market in New Zealand

The HPV Testing market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for HPV Testing Market in New Zealand

HPV Testing in New Zealand: rules and payment

Medical devices do not need approval before sale, but suppliers must notify them to the WAND database run by Medsafe.⁠[1] Pharmac decides which medicines and medical devices the public health system pays for.⁠[2]

[1] Medsafe. Checked 14 Nov 2026.

[2] Pharmac. Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how HPV Testing products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in New Zealand.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in HPV Testing right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

HPV Testing in context

New Zealand compared

  • Health spending per person: 5,022 US$ per person (2024). World: 1,317 US$ per person (2023). 2nd highest of the 15 countries we cover in APAC.[1]
  • Doctors: 3.61 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 2nd highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 17.6% of people (2025). World: 10.4% of people (2025). 4th highest of the 16 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 17 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 18 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 18 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the HPV Testing market in New Zealand?
Placeholder estimate: about $14.7 Mn in 2025, rising to about $39.9 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the HPV Testing market in New Zealand growing?
Placeholder estimate: about 11.7% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the HPV Testing market report cover?
The report splits the market by test (HPV DNA Tests, HPV mRNA Tests, Genotyping Tests), sample (Clinician-Collected, Self-Collected) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the HPV Testing market?
Key players include Roche Diagnostics, Hologic, Inc., Qiagen N.V., BD (Becton, Dickinson) and Abbott Laboratories.
What is driving the HPV Testing market?
Greater awareness of women's health needs, more funding for female-focused research, later pregnancies and an ageing female population are driving the HPV Testing market. New products designed around women's biology and digital care are improving access.
Who regulates HPV Testing in New Zealand?
Medical devices do not need approval before sale, but suppliers must notify them to the WAND database run by Medsafe. Source: Medsafe. Checked 14 Nov 2026.
How is healthcare paid for in New Zealand?
Pharmac decides which medicines and medical devices the public health system pays for. Source: Pharmac. Checked 14 Nov 2026.
How much research is published on HPV Testing?
PubMed lists 1,549 papers on HPV Testing added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Medical Devices reports in New Zealand

See all

Related on women's health and oncology

See the topic